Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.43 USD | -5.70% | -.--% | -5.70% |
Sales 2024 * | 36.59B 227M 17.92B | Sales 2025 * | 39.05B 242M 19.12B | Capitalization | 141B 873M 69.01B |
---|---|---|---|---|---|
Net income 2024 * | -852M -5.27M -417M | Net income 2025 * | 2.54B 15.71M 1.24B | EV / Sales 2024 * | 4.33 x |
Net Debt 2024 * | 17.38B 108M 8.51B | Net cash position 2025 * | 14.05B 87.01M 6.88B | EV / Sales 2025 * | 3.25 x |
P/E ratio 2024 * |
60.5
x | P/E ratio 2025 * |
26.6
x | Employees | 350 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.88% |
Latest transcript on Nxera Pharma Co., Ltd.
1 day | -5.70% | ||
1 month | +6.31% | ||
3 months | -10.41% | ||
6 months | -5.70% | ||
Current year | -5.70% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 19/09/17 |
Shinichi Tamura
FOU | Founder | 74 | 21/06/90 |
Director of Finance/CFO | - | 23/03/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 21/06/90 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 26/03/19 |
Rolf Soderstrom
BRD | Director/Board Member | 59 | 24/03/20 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.08% | 95.18B | |
-0.13% | 37.55B | |
-10.43% | 33.75B | |
+77.76% | 28.2B | |
-14.82% | 15.63B | |
-3.06% | 13.63B | |
-12.76% | 11.5B | |
+181.73% | 10.81B | |
-53.92% | 9.23B |
- Stock Market
- Equities
- 4565 Stock
- SOLTF Stock